Enovation and Verklizan join forces strengthening its position in the Connected Healthcare market. The combination of the two companies creates a European leading healthcare SaaS player active in over 18 countries with a strong position across a wide variety of verticals including hospitals, general practitioners, home- and elderly care and alarm centers. Enovation is backed by strategic software investor Main Capital and is currently executing a buy-and-build strategy to further grow internationally while strengthening the product- and services proposition. Main was also already a majority shareholder in Verklizan.
Verklizan established a leading position in the Connected Healthcare market serving over 300 customers in several European countries from its offices in the Netherlands, Germany, England and Spain. The UMO platform developed by Verklizan monitors over 1,500,000 people daily, enabling patients to live longer at home. The technology supports healthcare organizations improving the quality and efficiency of care provision helping customers to cope with challenges related to scarcity of resources and the ageing of the population. Examples of customers using the UMO platform are Sensire (NL), Red Cross (GER and SP), Centra Pulse (UK) and DoroCare ARC (SE).
The combination of both companies creates a leading European healthcare SaaS vendor in the €40m revenue range employing over 250 people. As the products of both companies are complementary, a joint Connected Healthcare solution will be brought to market driven by trends like the ageing of the population, the desire of patient to stay home for a longer period and pressures on healthcare costs. With a platform comprising various healthcare communication solutions, Enovation & Verklizan can jointly offer patient monitoring solutions that can be fully integrated into the processes of healthcare organizations. The independent position of the combined company allows to efficiently incorporate patient monitoring and communication solutions in the established processes of healthcare organizations leveraging integrations with local healthcare IT systems and devices. This enables healthcare organizations to increase efficiency and provides healthcare professionals with accurate real-time information allowing them to focus on providing high-quality care.
The combination with Verklizan is the second strategic acquisition of Enovation since the entry of Main Capital in September 2018 as the company acquired XDS vendor Meddex in December 2018. Enovation envisions to further grow towards a leading SaaS player in the global Healthcare market leveraging organic growth and following a selective buy-and-build strategy.
Jeroen van Rijswijk (CEO Enovation): “The Verklizan solution is a perfect addition to our communication and integration platform. This enables us as an independent company to offer a total solution in which patients can exchange ehealth data, e.g. measurements and alarm data in a simple and reliable manner with care providers which is fully integrated with their information systems. This is unique in the Connected care market.”
Riny van Zandwijk (CEO Verklizan): “Together with Enovation, Verklizan will be able to distribute the valuable data, collected on its independent UMO platforms all over Europe, through the full care chain on an efficient and secure way. This information, received from more than 250 telecare and telehealth devices, will enable new technology supported services and prevention for large groups of vulnerable people in Europe and will be a means to control the ever growing costs of healthcare.”
Charly Zwemstra (Chairman of the Board Enovation and Managing Partner Main Capital Partners): “The combination with Verklizan strengthens Enovation’s position in the European Connected Healthcare market. This aligns well with Main Capital’s strategy of supporting software companies to grow (internationally), both organically and via a strategic buy-and-build strategy.”
For over 35 years, Enovation is the specialist for secure healthcare communication solutions. The company focuses on facilitating information exchange between- and within healthcare institutions and between healthcare institutions and patients. The company’s product proposition comprises own developed IP solutions complemented with solutions of partners. The solutions are based on (international) standards and can be seamlessly integrated with existing processes and IT systems of healthcare institutions.
Verklizan is a Dutch supplier of the UMO platform, a platform for social alarming, remote care, welfare and safety. Verklizan is characterized by its open platform philosophy that supports the connection of the UMO platform with more than 250 healthcare products and technological developments of over 100 product partners. This gives the customers of Verklizan the freedom and opportunity to continuously provide the best and technologically most advanced remote care.
About Main Capital
Main Capital is a strategic investor with an exclusive focus on the software sector in the Benelux, Germany and Scandinavia. Within this sector, we are the most specialized party in majority buy-outs and later-stage growth capital for acquisitions. Main Capital has approximately € 450 million under management for investments in mature but growing software companies in the Netherlands, Germany and The Nordics. An experienced team of professionals manages these Private Equity funds from offices in The Hague and Düsseldorf. Main Capital has a strong footprint in the healthcare SaaS market and acquired companies like Enovation, SDB Ayton, Verklizan, RVC Medical IT and The Patient Safety Company before.
The current and former investment portfolio of Main Capital consists of growing (SaaS) software companies such as Enovation, SDB Ayton, GOconnectIT, JobRouter, Inergy, MUIS Software, artegic, OBI4wan, Axxerion, b+m Informatik, Ymor, Roxit, Onguard, Sharewire, SecondFloor, Sofon and ChainPoint. Main Capital has a long-term perspective with the intention to build larger strong software groups.
Note for the editor:
For more information, please contact:
Charly Zwemstra (Managing Partner)
Main Capital Partners BV, Paleisstraat 6, 2514 JA, Den Haag
Tel: +31 (0) 70 324 3433 / +31 (0) 6 512 77 805